And just for good order. These are the remaining trials the company is or is planning to run or sponsor. All according to the recent prospectus. There is also a lot ongoing below the surface in the Xyotax area. Not so surprising that they are burning so much cash.
Erik
XYOTAX
• NSCLC (second-line; “STELLAR 2”)
III / enrollment completed
• NSCLC in combination with carboplatin (front-line PS2; “STELLAR3”)
III / enrollment completed
• NSCLC (front-line PS2; “STELLAR4”)
III / enrollment completed
• Ovarian front-line maintenance (GOG) (0212)
III / 2H04
• Ovarian second relapse (GOG) (186c)
II / open
• Ovarian front-line dose escalation (GOG) (9914)
I/II / open
• Ovarian first-line in combination with carboplatin (201)
II / open
• Advanced solid tumors in combination with cisplatin (1055)
I / open
• Advanced solid tumors, single agent—dosing every week (102)
I / open
• Advanced solid tumors, single agent—dosing every 3 weeks (1052)
I / enrollment completed
• NSCLC first-line, combined with carboplatin (202)
II /open
• NSCLC salvage, single agent (105)
I / open
• Advanced solid tumors combined with carboplatin (1072)
I / enrollment completed
• Combination with cisplatin and radiation for esophageal and gastric cancer (104)
I / open
• Lung cancer, in combination with radiation (103)
I / open
Pixantrone
• Aggressive NHL, ³3 relapses, single agent (301)
III / open
• Relapsed aggressive NHL, BSHAP (II-02)
II / open
• Aggressive NHL, front-line, CPOP-R (II-03)
II / 05
• Relapsed AML, single agent (I-09)
I / 05
• Relapsed indolent NHL, FND-R (I-06)
I/II / enrollment completed
• Relapsed aggressive NHL, BSHAP
I / enrollment completed
• Relapsed aggressive NHL, CPOP (I-07)
I/II / open
CT-2106
• Advanced solid tumors, single agent—dosing every 3 weeks (101)
I / enrollment completed
• Advanced solid tumors, single agent—dosing every week (102)
I / 05
• Small cell lung cancer (202)
II / 05
• Relapsed ovarian cancer (203)
II / 05
• Relapsed colorectal cancer (201)
II / open
|
